Ubs Group Ag Theravance Biopharma, Inc. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 174,245 shares of TBPH stock, worth $1.62 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

174,245

Previous 30,757 466.52%

Holding current value

$1.62 Million

Previous $247,000 563.56%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$7.93 - $10.08 $1.14 Million - $1.45 Million	143,488 Added 466.52%	174,245 $1.64 Million
Q3 2024 Nov 14, 2024	SELL	$7.66 - $10.25 $23,094 - $30,903	-3,015 Reduced 8.93%	30,757 $247,000
Q2 2024 Aug 13, 2024	SELL	$8.29 - $9.92 $209,877 - $251,144	-25,317 Reduced 42.85%	33,772 $286,000
Q1 2024 May 13, 2024	SELL	$8.22 - $11.59 $97,957 - $138,118	-11,917 Reduced 16.78%	59,089 $530,000
Q4 2023 Feb 09, 2024	BUY	$8.58 - $11.4 $148,331 - $197,083	17,288 Added 32.18%	71,006 $798,000
Q3 2023 Nov 09, 2023	BUY	$8.38 - $10.44 $92,238 - $114,913	11,007 Added 25.77%	53,718 $463,000
Q2 2023 Aug 11, 2023	BUY	$10.16 - $11.92 $162,427 - $190,565	15,987 Added 59.82%	42,711 $442,000
Q1 2023 May 12, 2023	BUY	$9.87 - $11.44 $178,331 - $206,697	18,068 Added 208.73%	26,724 $289,000
Q4 2022 Feb 08, 2023	BUY	$9.65 - $11.34 $82,565 - $97,025	8,556 Added 8556.0%	8,656 $97,000
Q3 2022 Nov 10, 2022	SELL	$8.39 - $10.22 $1,619 - $1,972	-193 Reduced 65.87%	100 $1,000
Q2 2022 Aug 10, 2022	SELL	$8.41 - $10.34 $27,382 - $33,667	-3,256 Reduced 91.74%	293 $2,000
Q1 2022 May 16, 2022	BUY	$8.33 - $12.96 $9,171 - $14,268	1,101 Added 44.98%	3,549 $34,000
Q4 2021 Feb 14, 2022	BUY	$7.42 - $11.05 $12,487 - $18,597	1,683 Added 220.0%	2,448 $27,000
Q3 2021 Nov 15, 2021	BUY	$6.77 - $14.41 $4,502 - $9,582	665 Added 665.0%	765 $6,000
Q2 2021 Aug 13, 2021	SELL	$14.52 - $22.46 $3.18 Million - $4.92 Million	-218,938 Reduced 99.95%	100 $1,000
Q1 2021 May 12, 2021	BUY	$16.57 - $21.08 $842,402 - $1.07 Million	50,839 Added 30.23%	219,038 $4.47 Million
Q4 2020 Feb 11, 2021	BUY	$14.89 - $20.16 $1.27 Million - $1.72 Million	85,425 Added 103.2%	168,199 $2.99 Million
Q3 2020 Nov 12, 2020	BUY	$14.79 - $22.49 $1.19 Million - $1.8 Million	80,249 Added 3178.18%	82,774 $1.22 Million
Q2 2020 Jul 31, 2020	SELL	$20.64 - $30.69 $40,309 - $59,937	-1,953 Reduced 43.61%	2,525 $53,000
Q1 2020 May 01, 2020	BUY	$17.84 - $31.21 $34,841 - $60,953	1,953 Added 77.35%	4,478 $104,000
Q4 2019 Feb 14, 2020	SELL	$16.12 - $25.89 $3.18 Million - $5.12 Million	-197,577 Reduced 98.74%	2,525 $65,000
Q3 2019 Nov 14, 2019	BUY	$16.51 - $23.78 $3.18 Million - $4.58 Million	192,545 Added 2547.9%	200,102 $3.9 Million
Q2 2019 Aug 14, 2019	BUY	$15.6 - $25.15 $40,731 - $65,666	2,611 Added 52.79%	7,557 $123,000
Q1 2019 May 14, 2019	SELL	$22.57 - $28.15 $554,003 - $690,969	-24,546 Reduced 83.23%	4,946 $112,000
Q4 2018 Feb 14, 2019	BUY	$22.52 - $35.07 $525,256 - $817,972	23,324 Added 378.15%	29,492 $754,000
Q3 2018 Nov 14, 2018	BUY	$22.83 - $32.67 $70,384 - $100,721	3,083 Added 99.94%	6,168 $201,000
Q2 2018 Aug 14, 2018	SELL	$22.06 - $25.52 $31,457 - $36,391	-1,426 Reduced 31.61%	3,085 $70,000
Q1 2018 May 15, 2018	BUY	$23.37 - $29.71 $49,474 - $62,896	2,117 Added 88.43%	4,511 $109,000
Q4 2017 Feb 14, 2018	SELL	$25.82 - $35.66 $124,581 - $172,059	-4,825 Reduced 66.84%	2,394 $67,000
Q3 2017 Nov 14, 2017	BUY	$23.88 - $34.96 $114,480 - $167,598	4,794 Added 197.69%	7,219 $247,000
Q2 2017 Aug 14, 2017	BUY	N/A	2,225 Added 1112.5%	2,425 $96,000
Q1 2017 Nov 14, 2017	BUY	N/A	200	200 $7,000

Others Institutions Holding TBPH

# of Institutions

129

Shares Held

46.5M

Call Options Held

600

Put Options Held

300

View Full List

About Theravance Biopharma, Inc.

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $622M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

More about TBPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account